Rezdiffra (Resmetirom) Adolescent (12, 17) Dosing

What Is Resmetirom and Why Does Adolescent Dosing Matter?

Resmetirom (brand name Rezdiffra) is the first medication approved specifically for metabolic dysfunction-associated steatohepatitis (MASH), the condition formerly called NASH. The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, which demonstrated histological improvement in adults with liver fibrosis stages F2 and F3 [1]. The drug works as a selective agonist of thyroid hormone receptor beta (THR-beta), a receptor concentrated in hepatocytes that regulates lipid metabolism, mitochondrial function, and hepatic fat clearance [2].

Pediatric MASH is not rare. Autopsy-based studies estimate that 9.6% of U.S. children and adolescents have non-alcoholic fatty liver disease (NAFLD), with higher rates among Hispanic and obese youth [3]. Among obese adolescents referred for liver evaluation, biopsy-confirmed MASH may affect 1 to 2 out of every 100. Yet no pharmacotherapy carries a pediatric MASH indication. This gap leaves clinicians, parents, and adolescent patients asking whether resmetirom could fill it. The short answer: not yet, and not without significant unknowns.

Current FDA-Approved Adult Dosing

The approved adult regimen uses a weight-based threshold. Patients weighing under 100 kg take 80 mg once daily. Those at or above 100 kg take 100 mg once daily. Both doses are oral tablets taken with food [4]. The prescribing information specifies that treatment should be limited to patients with non-cirrhotic MASH confirmed by liver biopsy or non-invasive testing, combined with fibrosis stage F2 or F3.

In MAESTRO-NASH (N=966), the 80 mg dose achieved MASH resolution without worsening of fibrosis in 25.9% of patients at 52 weeks, compared to 9.7% on placebo. The 100 mg dose reached 29.9% [1]. Fibrosis improvement by at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% for placebo [1]. These results apply to adults aged 18 and older. No subgroup analysis included anyone younger.

The prescribing information does not provide dose adjustments for adolescents. It does not include pharmacokinetic data in patients under 18. There is no pediatric section in the label beyond a single line stating that safety and effectiveness have not been established in pediatric patients [4].

Why No Adolescent Data Exist Yet

Drug development timelines explain the gap. Resmetirom moved through adult trials over more than a decade. The MAESTRO-NASH trial enrolled adults from 2019 to 2023, and the FDA's accelerated approval pathway prioritized adult histological endpoints. Pediatric studies typically follow adult approval, often prompted by a Pediatric Research Equity Act (PREA) requirement or a Written Request from the FDA [5].

Madrigal Pharmaceuticals has not publicly disclosed a pediatric development plan for resmetirom as of May 2026. The FDA's PREA framework could require pediatric studies if the drug's indication is relevant to a pediatric population, which MASH clearly is. However, PREA timelines allow deferrals, and no pediatric trial registry entries (ClinicalTrials.gov) list resmetirom in patients under 18.

The absence of data is not evidence of harm. It is simply a gap. But that gap matters because adolescent physiology introduces variables that adult trials did not address.

Physiological Concerns Specific to Adolescents

Thyroid hormone signaling plays a direct role in skeletal maturation, linear growth, and pubertal development. Resmetirom is designed to be liver-selective and THR-beta-specific, sparing the THR-alpha receptor that mediates cardiac and bone effects [2]. In adults, this selectivity translates to a favorable safety profile: the MAESTRO-NASH trial showed no clinically significant changes in heart rate, bone density, or TSH levels at 52 weeks [1].

Adolescent biology complicates this picture. Growth plates remain open until late puberty, and even modest perturbation of thyroid hormone signaling in bone could theoretically alter final adult height. A 2021 review in the Journal of Clinical Endocrinology & Metabolism noted that THR-beta is expressed in growth-plate chondrocytes, though at lower levels than THR-alpha [6]. Whether resmetirom's selectivity ratio is sufficient to avoid growth-plate effects in a 13-year-old remains untested.

Hepatic metabolism also changes during puberty. Cytochrome P450 enzyme activity, particularly CYP3A4 and CYP2C8, shifts between ages 12 and 17. Resmetirom is primarily metabolized by CYP3A4 [4]. A dose that produces target drug levels in a 45-year-old may produce different exposure in a 14-year-old with the same body weight but different enzyme maturation.

Body composition adds another variable. Adolescents carry proportionally more lean mass relative to fat mass compared to the middle-aged adults in MAESTRO-NASH. Because resmetirom distributes into hepatic tissue and is highly protein-bound (approximately 99%), differences in albumin levels, liver blood flow, and fat-free mass could shift the pharmacokinetic profile in unpredictable ways.

What Pediatric Hepatologists Are Watching For

Specialists in pediatric liver disease have expressed cautious interest in THR-beta agonism as a therapeutic strategy for adolescent MASH, but consensus statements emphasize that lifestyle intervention remains first-line. The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) published updated NAFLD guidance in 2022 recommending diet, exercise, and vitamin E (800 IU/day for biopsy-proven NASH in children over 8) as the primary interventions [7]. No pharmacologic agent beyond vitamin E has sufficient pediatric evidence to earn a guideline recommendation.

If resmetirom enters pediatric trials, hepatologists will monitor several endpoints beyond histology. Linear growth velocity (measured every 3 to 6 months) would detect early skeletal effects. Bone-age radiographs could identify premature or delayed epiphyseal maturation. Free T4, free T3, and TSH levels would track thyroid axis perturbation. Lipid panels matter because THR-beta agonism lowers LDL cholesterol and triglycerides; in MAESTRO-NASH, LDL dropped by approximately 14% at 52 weeks with the 100 mg dose [1]. Whether this degree of lipid lowering is safe or beneficial in a growing adolescent requires dedicated study.

Mental health screening deserves specific attention. Adolescents with obesity and liver disease carry higher rates of depression and anxiety. Any new medication in this population should be evaluated for neuropsychiatric effects, even if the adult trial showed none.

Off-Label Use: Risks and Realities

Some clinicians may consider off-label resmetirom for adolescents with severe, progressive MASH and fibrosis, particularly those who have failed lifestyle interventions and vitamin E. Off-label prescribing is legal in the United States, but it carries clinical, ethical, and medicolegal implications that are magnified in minors.

The American Academy of Pediatrics (AAP) has stated that off-label use of medications in children should be supported by "some evidence of safety and efficacy in the pediatric population" [8]. For resmetirom, that evidence does not exist. No case series, no compassionate-use reports, and no pharmacokinetic bridging studies have been published in patients under 18.

If a clinician proceeds with off-label use, several safeguards would be essential. The prescribing physician should be a pediatric hepatologist or gastroenterologist with MASH expertise. Informed consent (and assent from the adolescent) should explicitly address the investigational nature of the use. A monitoring protocol covering thyroid function, liver enzymes, lipids, growth velocity, and bone age should be established before the first dose. Dosing, lacking any pediatric pharmacokinetic data, would likely start at the lower adult dose (80 mg daily) regardless of weight, with slow titration and frequent lab checks.

Weight-Based Dosing Extrapolation: Why It Falls Short

Scaling an adult dose by body weight is common in pediatric medicine, but it has well-known limitations. Allometric scaling (adjusting dose by weight raised to the 0.75 power) better predicts clearance across body sizes, but it requires knowing the drug's volume of distribution and clearance values in the target population [9]. For resmetirom, published pharmacokinetic data come exclusively from adults.

The adult weight-based cutoff (80 mg for under 100 kg, 100 mg for 100 kg and above) was derived from exposure-response modeling in the MAESTRO-NASH population, where the median age was 56 years and the median BMI was approximately 34 [1]. An adolescent weighing 85 kg may have a BMI of 32 if they are 5 feet 6 inches tall, but their organ maturation, protein binding, and hepatic blood flow differ from those of a 56-year-old with the same BMI. Simple weight-based extrapolation could lead to under-dosing (inadequate hepatic exposure) or over-dosing (thyroid axis suppression).

Population pharmacokinetic modeling in a dedicated adolescent cohort is the minimum prerequisite before any evidence-based dose recommendation can be made. This work has not been done.

How Resmetirom Compares to Other Emerging Pediatric MASH Options

Resmetirom is not the only drug being discussed for adolescent MASH. GLP-1 receptor agonists, particularly semaglutide and liraglutide, have pediatric approvals for obesity (semaglutide received FDA approval for obesity in adolescents aged 12 and older in late 2022) and are being studied for their hepatic benefits in this age group [10]. The STEP TEENS trial (N=201) showed 16.1% mean body-weight reduction with semaglutide 2.4 mg versus 0.6% with placebo at 68 weeks in adolescents aged 12 to 17 [10]. While not a MASH-specific endpoint, weight loss of this magnitude is associated with histological improvement in fatty liver disease.

Obeticholic acid (Ocaliva), a farnesoid X receptor agonist, was studied in adults with NASH but carries a black-box warning for hepatic decompensation and has no pediatric data [11]. Lanifibranor, a pan-PPAR agonist, completed the phase 3 NATiV3 trial in adults and may eventually be studied in younger populations, but no pediatric protocol is registered.

For now, the only pharmacotherapy with pediatric MASH evidence is vitamin E, supported by the TONIC trial (N=173), which showed NASH resolution in 58% of children treated with vitamin E 800 IU/day versus 28% with placebo at 96 weeks [12]. Vitamin E remains the only option with a guideline-level recommendation from NASPGHAN for pediatric NASH [7].

What Parents and Adolescents Should Know

If your adolescent has been diagnosed with MASH, the most important step is establishing care with a pediatric gastroenterologist or hepatologist experienced in fatty liver disease. Ask specifically about fibrosis staging, either through liver biopsy or validated non-invasive tools like the Pediatric NAFLD Fibrosis Index or transient elastography (FibroScan).

Lifestyle modification works. A meta-analysis of 10 randomized trials in children and adolescents with NAFLD found that structured diet and exercise programs reduced hepatic steatosis by an average of 5.3 percentage points on MRI-PDFF compared to standard care [13]. These effects are modest but meaningful, and they carry no pharmacologic risk.

If a provider suggests resmetirom for your teenager, ask these questions: What evidence supports this use in someone under 18? What monitoring plan is in place for thyroid function, growth, and bone health? Has the provider consulted with the drug manufacturer or applied for compassionate use? Is there a clinical trial your adolescent might be eligible for?

The Path Forward for Pediatric Resmetirom Research

The FDA's accelerated approval of resmetirom includes a requirement for confirmatory trials. Madrigal must complete MAESTRO-OUTCOMES, a cardiovascular outcomes study in adults, to convert the accelerated approval to full approval. Pediatric studies, if mandated under PREA, would follow.

A realistic timeline for a pediatric pharmacokinetic and safety study might involve a phase 1/2 open-label trial in adolescents aged 12 to 17 with biopsy-confirmed MASH and fibrosis stage F2 or higher. Such a trial would likely enroll 30 to 60 participants, run for 24 to 52 weeks, and use pharmacokinetic sampling at steady state to model appropriate doses. If results are favorable, a larger efficacy trial with histological endpoints would follow.

Until that data exists, the evidence-based approach for adolescent MASH remains lifestyle intervention first, vitamin E for biopsy-confirmed NASH, and GLP-1 receptor agonists for co-existing obesity. Resmetirom should be reserved for clinical trial participation or carefully supervised off-label use in adolescents with progressive fibrosis who have exhausted other options, and only under the direction of a pediatric hepatologist with a structured monitoring protocol in place.